파트너 소식

[Webina] High-Quality Plasmid DNA Manufacturing Strategies for Gene and Cell Therapeutics

2021-10-21 09:44

Title: High-Quality Plasmid DNA Manufacturing Strategies for Gene and Cell Therapeutics
Date: Oct 27, 2021 11:00 - 12:00 (GMT+2)
Duration: 1 hour


Join us for this live webinar to learn about GenScript's High-Quality Plasmid DNA Manufacturing for Gene and Cell therapeutics, and how GenScript ProBio, the biopharmaceutical CDMO segment of GenScript Biotech Corporation can support you with your projects.

Success in gene and cell therapy has increased the demand for high-quality plasmid DNA production and the Gene and Cell Therapy (GCT) business line of GenScript ProBio has achieved great success in this space since it launched in 2019.

In this webinar, Dr. Ming Ni, the CMC Project Manager for GenScript ProBio will provide a high-level overview of his experience in dealing with the challenges of plasmid production. The session will include plenty of time for questions after the following topics have been addressed:

+The plasmids definition for different gene and cell therapeutics
+Optimization of the plasmid manufacturing process
+Plasmid manufacturing for cell therapy products & mRNA vaccines
+GenScript ProBio's GMP plasmids manufacturing experience

GenScript ProBio is dedicated to developing cutting-edge technologies to support the process development and production of plasmid DNA and different viral vectors. The platform has over 10 years of experience in producing plasmid DNA and has successfully delivered products for pre-clinical studies, IND filing, and clinical trials for clients worldwide. For the production of adeno-associated virus (AAV) vector, GenScript ProBio is able to provide suspension cultures with a manufacturing scale-up to 200L. In addition, GenScript ProBio is also capable of producing lentiviral vector (LVV) for cell therapy products and has experience in producing HSV, vaccinia virus, to support oncolytic virus development.

GenScript ProBio has a proven track record in producing plasmid DNA, with highlights including:

+10 IND approvals from FDA & NMPA & PMDA & MFDS
+>50 ongoing plasmid CMC projects for IND filing
+>50 clinical GMP plasmid batches for clinical trials
+Applications for CAR-T, TCR-T, CAR-NK, mRNA vaccine, DNA vaccine, gene therapy, lcDNA, CRISPER editing, etc.

About the event:

This session will be run in a live format using Zoom Webinar, with registration open for both OBN Members and Non-Members.

Keynote will be followed by an audience Q&A.

OBN Members - Complimentary
Non-Members - £25+VAT

For all event inquiries, please contact

Terms and Conditions of OBN Events

0bf42c0c-b0e7-4e63-a69a-83b8fda9006d.png Dr. Ming Ni
CMC Project Manager, Project Management Department at Genscript
Dr. Ming Ni received his doctoral degree from the University of Washington. He joined GenScript in January 2020 and has been responsible for technical support of the plasmid DNA platform. He led the plasmid DNA project to improve the yield and optimize purification steps. Before he joined GenScript, he was a full professor and department head of the Biomedical Engineering Department at Yachay Tech University. With over 50 peer-reviewed articles, 1600 citations, and 4 US patents, he is one of the most prolific scientists at GenScript.